Document is current
Any future updates will be listed below
-
Authors
Guay, Charles-Antoine
Maltais, François
Beaudoin, Claudia
Carmichael, Pierre-Hugues
Laouan Sidi, Elhadji Anassour
Perreault, Laurie
Sirois, Caroline
Provencher, Steeve
-
Funding
Funding for this research was provided by:
Fonds de Recherche du Québec - Santé (331071)
- License Information
-
More Information
Article History
Received: 18 May 2024
Accepted: 6 September 2024
First Online: 13 September 2024
Declarations
:
: This study involved aggregated human data and do not contains any individual person’s data. This study was reviewed and approved by the Laval University institutional review board (2021 − 271).
: Not applicable.
: Charles-Antoine Guay reports financial support was provided by Quebec Health Research Fund. Francois Maltais reports a relationship with GlaxoSmithKline that includes: funding grants and speaking and lecture fees. Francois Maltais reports a relationship with AstraZeneca that includes: consulting or advisory and funding grants. Francois Maltais reports a relationship with Sanofi that includes: funding grants. Francois Maltais reports a relationship with Novartis that includes: funding grants and speaking and lecture fees. Francois Maltais reports a relationship with Boehringer Ingelheim that includes: funding grants and speaking and lecture fees. Francois Maltais reports a relationship with Grifols that includes: funding grants and speaking and lecture fees. Francois Maltais reports a relationship with Oxynov that includes: equity or stocks. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
: None.
